<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579772</url>
  </required_header>
  <id_info>
    <org_study_id>6015083</org_study_id>
    <nct_id>NCT02579772</nct_id>
  </id_info>
  <brief_title>Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction</brief_title>
  <official_title>Systemic Vascular Dysfunction in COPD Patients With Mild-to-moderate Airflow Obstruction: Pharmacological Treatment With N-acetylcysteine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether pharmacological treatment with
      N-acetylcysteine improves central and peripheral cardiorespiratory control and physical
      capacity in COPD patients with mild-to-moderate airflow obstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality
      worldwide. Cardiovascular complications constitute the main causes of poor physical capacity
      and healthcare resources utilization in COPD. There is emerging evidence that these
      impairments have a major impact on the health of patients with mild-to-moderate disease, the
      largest sub-population of COPD. This important problem, however, is currently neglected as no
      specific pharmacological treatment is offered to these patients. Recent studies indicate that
      vascular abnormalities are mediated, at least in part, by circulating inflammatory substances
      and direct damage of the arteries by oxygen radicals (oxidative stress). The current
      investigation will test the hypothesis that N-acetylcysteine (NAC), via its anti-inflammatory
      and antioxidant properties, improves systemic vascular function and physical capacity in COPD
      patients with mild-to-moderate airflow obstruction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Redox Status - Circulating Glutathione</measure>
    <time_frame>pre-exercise value (day 4)</time_frame>
    <description>Fluorescent detection of plasma glutathione from samples collected during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exercise Capacity - Time to Exhaustion</measure>
    <time_frame>end-exercise value (Day 4)</time_frame>
    <description>Cycling time to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Central Cardiovascular Function - Cardiac Output</measure>
    <time_frame>end-exercise value (Day 4)</time_frame>
    <description>During cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Skeletal Muscle Deoxygenation - Dynamics (Mean Response Time)</measure>
    <time_frame>Day 4</time_frame>
    <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Skeletal Muscle Vascular Function - Capillary Blood Flow Dynamics (Mean Response Time)</measure>
    <time_frame>Day 4</time_frame>
    <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Oxygen Uptake - Dynamics (Mean Response Time)</measure>
    <time_frame>Day 4</time_frame>
    <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Ventilation - Minute Ventilation (VE)</measure>
    <time_frame>end-exercise value (Day 4)</time_frame>
    <description>During cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pharmacological treatment with N-acetylcysteine (NAC) pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>NAC pills</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable COPD with mild-to-moderate airflow obstruction as indicated by the low ratio
             between forced expiratory volume in one second and forced vital capacity
             (FEV1/FVC&lt;0.7) together with post-bronchodilator FEV1≥60% predicted under optimized
             clinical treatment as judged by the accompanying physician

        Exclusion Criteria:

          -  unable to perform all experimental procedures and/or provide informed consent;

          -  hospital admission in the previous 6 weeks;

          -  exercise training program in the previous 6 months;

          -  any condition that could interfere with the ability to exercise;

          -  diagnosed psychiatric or cognitive disorders;

          -  type I insulin-dependent diabetes mellitus;

          -  excessively over-weight (BMI&gt;35kg/m²);

          -  other diagnosed cardiorespiratory disorders (e.g., chronic heart failure, peripheral
             artery disease).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Alberto Neder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <results_first_submitted>March 2, 2018</results_first_submitted>
  <results_first_submitted_qc>May 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2018</results_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. J. Alberto Neder</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine, Then Placebo</title>
          <description>Participants first received N-acetylcysteine (NAC; 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment). After a washout period of at least 7 days, they then received 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then N-acetylcysteine</title>
          <description>Participants first received 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment. After a washout period of at least 7 days, they then received N-acetylcysteine (NAC; 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Usage of additional antioxidants</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>flu-like illness, orthopedic trauma</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomized to receive either N-acetylcysteine (NAC) or placebo pills</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Redox Status - Circulating Glutathione</title>
        <description>Fluorescent detection of plasma glutathione from samples collected during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
        <time_frame>pre-exercise value (day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Redox Status - Circulating Glutathione</title>
          <description>Fluorescent detection of plasma glutathione from samples collected during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
          <units>micromolar</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="0.61"/>
                    <measurement group_id="O2" value="7.05" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Exercise Capacity - Time to Exhaustion</title>
        <description>Cycling time to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
        <time_frame>end-exercise value (Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Capacity - Time to Exhaustion</title>
          <description>Cycling time to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336" spread="51"/>
                    <measurement group_id="O2" value="325" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Cardiovascular Function - Cardiac Output</title>
        <description>During cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
        <time_frame>end-exercise value (Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Cardiovascular Function - Cardiac Output</title>
          <description>During cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
          <units>liters/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="1.0"/>
                    <measurement group_id="O2" value="12.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Skeletal Muscle Deoxygenation - Dynamics (Mean Response Time)</title>
        <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
        <time_frame>Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skeletal Muscle Deoxygenation - Dynamics (Mean Response Time)</title>
          <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="1.3"/>
                    <measurement group_id="O2" value="19.0" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Skeletal Muscle Vascular Function - Capillary Blood Flow Dynamics (Mean Response Time)</title>
        <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
        <time_frame>Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skeletal Muscle Vascular Function - Capillary Blood Flow Dynamics (Mean Response Time)</title>
          <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="4.6"/>
                    <measurement group_id="O2" value="66.5" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Oxygen Uptake - Dynamics (Mean Response Time)</title>
        <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
        <time_frame>Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Oxygen Uptake - Dynamics (Mean Response Time)</title>
          <description>Mean response time (MRT) evaluated during cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" spread="5.2"/>
                    <measurement group_id="O2" value="62.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulmonary Ventilation - Minute Ventilation (VE)</title>
        <description>During cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
        <time_frame>end-exercise value (Day 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine</title>
            <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Ventilation - Minute Ventilation (VE)</title>
          <description>During cycling to exhaustion during day 4 of each experimental arm (placebo vs. N-acetylcysteine)</description>
          <units>liters/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="7.6"/>
                    <measurement group_id="O2" value="75.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected over the 4-day treatment period (NAC and placebo).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine</title>
          <description>Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bloating, intestinal gas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. J. Alberto Neder</name_or_title>
      <organization>Queen's University</organization>
      <phone>613-548-2255</phone>
      <email>nederalb@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

